| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
When IPAG inhibits Sigma1, PD-L1 in PC3 (hormone-insensitive prostate cancer) and MDA-MB-231 (triple-negative breast cancer) cell lines is autolysosomally degraded, and the amount of functional PD-L1 on the cell surface cells is decreased [2]. 100±8 μg per 106 cells were generated on average after IPAG treatment. IPAG has the ability to stop cell division. Cell mass is decreased by IPAG therapy [3]. The phosphorylation of the translation regulatory proteins p70S6K, S6, and 4E-BP1 is inhibited by IPAG administration [3].
|
|---|---|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: T47D Cell Tested Concentrations: 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The average forward scatter height (FSC-H) of DMSO (control) measured 412±5, while the average FSC-H of IPAG The treated cells were 412±5 and 390±4. Western Blot Analysis [3] Cell Types: T47D Cell Tested Concentrations: 10 μM Incubation Duration: Experimental Results: diminished levels of phosphothreonine 389-p70S6 kinase (P-S6K), phosphoserine 235/236-ribosomal S6 (P-S6) , and phosphoserine 65-4E-BP1 (P-4E-BP1). |
| References |
|
| Additional Infomation |
IPAG is a potent sigma-receptor antagonist.
|
| Molecular Formula |
C17H22IN3
|
|---|---|
| Molecular Weight |
395.28115606308
|
| Exact Mass |
395.086
|
| CAS # |
193527-91-2
|
| PubChem CID |
4239764
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.615
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UUKPIWYXWLJPJF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H22IN3/c18-14-1-3-15(4-2-14)20-17(19)21-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16H,5-9H2,(H3,19,20,21)
|
| Chemical Name |
2-(2-adamantyl)-1-(4-iodophenyl)guanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~21.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5299 mL | 12.6493 mL | 25.2985 mL | |
| 5 mM | 0.5060 mL | 2.5299 mL | 5.0597 mL | |
| 10 mM | 0.2530 mL | 1.2649 mL | 2.5299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
